Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2024. Read More.
Open Access Percentage
55%
Total
Publications
895
Total Open
Publications
495
Total
Citations
82K
Open Access
Percentage
55%
Total
Publications
895
Total Open
Publications
495
Total
Citations
82K
Breakdown
Publisher Open
17%
Both
27%
Other Platform Open
9%
Closed
47%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 39%
148
Hybrid 26%
98
No Guarantees 35%
130
Other Platform Open
Domain 77%
244
Institution 24%
77
Other Internet 14%
45
Public 5%
16
Preprint 1%
2
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 245 |
DOI | Other Internet | 45 |
DANS - Data Archiving and Networked Services | Institution | 21 |
Figshare | Public | 15 |
DASH - Digital Access to Scholarship at Harvard | Institution | 15 |
Europe PMC | Domain | 8 |
Elsevier - Scopus | Institution | 8 |
University of Modena and Reggio Emilia - IRIS UNIMORE | Institution | 6 |
U.S. Department of Energy Office of Scientific and Technical Information - OSTI OAI | Institution | 6 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 4 |